Special Issue "Anti-SARS-CoV-2/COVID-19 Drugs and Vaccines"
Deadline for manuscript submissions: 31 December 2021.
Interests: vaccines; immunology; autoimmunity; cancer; chronic diseases; exercise; mental health; immunotherapy
Special Issues and Collections in MDPI journals
Special Issue in Cancers: Cancer Vaccines: Research and Applications
Special Issue in Vaccines: Therapeutic Approaches for Type 1 and Type 2 Diabetes
Special Issue in Brain Sciences: Advances in Multiple Sclerosis Research—Series I
Special Issue in Vaccines: Multiple Sclerosis and Its Complications: Clinical Trials
Special Issue in Brain Sciences: Advances in Multiple Sclerosis Research—Series II
Special Issue in Vaccines: Vaccines for Infectious and Chronic Diseases
Special Issue in International Journal of Molecular Sciences: Complimentary Medicine for the Treatment of Chronic and Infectious Diseases
Special Issue in Vaccines: Multiple Sclerosis, Complications and Therapeutics 2.0
Special Issue in Vaccines: Vaccine Immunology
Interests: vaccine development; conjugated vaccine; vaccine efficacy; drug addiction; drug delivery; nano drug delivery; nanotechnology; cancer treatment; nano-particles; nano-particulate drug delivery system
A novel strain of coronavirus, SARS-CoV-2, the causative agent of coronavirus disease (COVID-19) was first identified in late 2019 and triggered a pandemic which has been ongoing since March 2020. The pandemic has already had a serious impact on the global economy and has resulted thus far in over 2 million deaths and almost 100 million infections. The development of effective therapeutics is an urgent global priority to stop the spread of COVID-19 infections and prevent further fatalities. As such, a number of platforms such as drugs, vaccines, monoclonal antibodies, pharmacological therapy, plasma therapy, immune boosters, and alternative medicines have been explored. Researchers are fast-tracking this process, and there have already been significant developments during preclinical and clinical phases in a relatively short period. There are a number of drug candidates and vaccines developed for emergency use within a year, which is unprecedented in human history.
In this Special Issue of Biologics, the focus will be on the development of vaccines, pharmacological therapy, alternative medicines, monoclonal antibodies, plasma therapy, preclinical studies, clinical trials, replication, viral life cycle, and pathogenesis of SARS-CoV-2, as well as areas of identification of novel drug targets and any form of treatment models against COVID-19 infection. In vitro, in vivo, in silico, preclinical, and clinical trials are all welcome.
This Special Issue is for reviews or original research papers on biologics against the SARS-CoV-2 virus/COVID-19.
Prof. Dr. Vasso Apostolopoulos
Dr. Majid Hassanzadeganroudsari
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biologics is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- novel drugs
- pharmacological therapy
- monoclonal antibodies
- alternative medicine